|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Thomas_Schinecker
|
|
gptkbp:chairman
|
gptkb:Christoph_Franz
|
|
gptkbp:competitor
|
gptkb:Bayer
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:Sanofi
gptkb:AbbVie
gptkb:Amgen
gptkb:Novartis
GlaxoSmithKline
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:division
|
gptkb:Roche_Diagnostics
gptkb:Roche_Diabetes_Care
gptkb:Roche_Molecular_Diagnostics
gptkb:Roche_Pharmaceuticals
gptkb:Roche_Professional_Diagnostics
gptkb:Roche_Sequencing_Solutions
gptkb:Roche_Tissue_Diagnostics
|
|
gptkbp:focusArea
|
Neuroscience
Oncology
Immunology
Infectious diseases
Ophthalmology
Diagnostics
Personalized healthcare
|
|
gptkbp:founded
|
1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:fullName
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche
|
|
gptkbp:industry
|
Pharmaceuticals
Diagnostics
|
|
gptkbp:ISIN
|
CH0012032048
|
|
gptkbp:marketCap
|
over $200 billion (2023)
|
|
gptkbp:notableAcquisition
|
gptkb:Foundation_Medicine_(2018)
gptkb:Genentech_(2009)
Chugai Pharmaceutical (majority stake, 2002)
Flatiron Health (2018)
Spark Therapeutics (2019)
|
|
gptkbp:notableEvent
|
Acquisition of Genentech
COVID-19 diagnostics development
Development of PCR diagnostics
Launch of Herceptin (trastuzumab)
Launch of Tamiflu (oseltamivir)
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentCompany
|
nan
|
|
gptkbp:product
|
gptkb:Venclexta
gptkb:Actemra
gptkb:Alecensa
gptkb:Avastin
gptkb:Bactrim
gptkb:Bonviva
gptkb:Cellcept
gptkb:Cotellic
gptkb:Erivedge
gptkb:Esbriet
gptkb:Fuzeon
gptkb:Gazyva
gptkb:Hemlibra
gptkb:Herceptin
gptkb:Kadcyla
gptkb:MabThera
gptkb:Madopar
gptkb:Ocrevus
gptkb:Pegasys
gptkb:Perjeta
gptkb:Polivy
gptkb:Rituxan
gptkb:Roaccutane
gptkb:Rocephin
gptkb:Rozlytrek
gptkb:Tamiflu
gptkb:Tarceva
gptkb:Tecentriq
gptkb:Valium
gptkb:Xeloda
gptkb:Xenical
gptkb:Xofluza
gptkb:Zelboraf
gptkb:Zerit
gptkb:Zyloric
|
|
gptkbp:publiclyTraded
|
Yes
|
|
gptkbp:revenue
|
CHF 63.3 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
Bearer shares
Non-voting equity securities
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Chugai_Pharmaceutical
gptkb:Ventana_Medical_Systems
|
|
gptkbp:website
|
https://www.roche.com
|
|
gptkbp:bfsParent
|
gptkb:South_San_Francisco
gptkb:罗氏
gptkb:Sir_John_Bell
gptkb:SIX_Swiss_Exchange
gptkb:Versed
gptkb:Roche_Diagnostics_North_America
gptkb:AstraZeneca
gptkb:BioNTech
gptkb:Genentech
gptkb:Glooko_Inc.
gptkb:Merck
gptkb:Infinity_Pharmaceuticals
gptkb:Levi_Garraway
gptkb:Lucentis
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|